Sun pharma company

Today we are talking about the company SUN PHARMA.

The largest Indian company in emerging markets with a presence in over 80 markets. Brazil, Mexico, Russia, Romania and South Africa are some of our key emerging markets.

We are present across all major markets in Western Europe, Canada, Australia, New Zealand, Japan and China among others.

Our presence in emerging markets and the developing world enables our teams to cross-sell and build brands with ease.

VISION :

Reaching People And Touching Lives Globally As A Leading Provider Of Valued Medicines.

PASSION:

Infuse energy in everything that you do

Walk that extra mile

Inspire others

Do your best in every situation.

CODE OF CONDUCT:

Our Global Code of Conduct governs every aspect of our operations. Sun Pharma is a family of thousands of people, working across many countries, speaking multiple languages, and all united, with one common purpose: to make good health accessible and affordable to local communities and society at large. Through active fieldwork, dedicated research teams, and in recognition of the efforts who work behind the scenes to combat illness and disease, the Sun Pharmaceutical Group helps as many people as possible, to secure their right to good health. The way we work every day is important to us.

• 5 billion revenue.

• 4th largest worldwide company.

• 38000 employees across the globe.

The first among Indian pharmaceutical companies to realise and embrace the importance of investing in research, we invest up to 7-8% of our global revenues into Research and Development (R&D) every year.

Core strength lies in our ability to excel in developing generics and technologically complex products backed by our dedicated teams in formulations, process chemistry, and analytical development.,

Our capabilities extend beyond the development of differentiated products, including liposomal products, inhalers, lyophilized injections, nasal sprays, and controlled-release dosage forms.

Our R&D team comprises over 2,700 people.

This company will perform better in future.

Dilip Shanghvi

Dilip Shanghvi is the founder of Sun Pharmaceutical Industries Ltd. and has extensive industrial experience in the pharmaceutical industry.

Industry: Pharmaceuticals

Founder: Dilip Shanghvi

Products: Pharmaceuticals; Branded generic drugs; over-the-counter drugs; Speciality ...

Net income: ₹3,405 crore (US$430 million) (2022).

We maintain our buy rating on Sun Pharma as we like its non-reliance on US generic drugs and traction in its speciality drugs segment," said Jefferies which has raised the target price on the stock to ₹1,089 from ₹1,020. Is it the right time to buy/sell Sun Pharmaceutical Industries Ltd.

Ranbaxy Laboratories Limited

Sun Pharma Ranbaxy Merger

Sun Pharma completed the acquisition of Ranbaxy Laboratories Limited, an integrated, research based, international pharmaceutical company, on 25th March 2015.

terms of operating profit margin, Sun Pharma is leading with a five-year average of 17.5 percent, whereas for Cipla, it is 16.7 percent. The five-year average net profit margin for Sun Pharma stands at 9.3 percent whereas it is 7.4 percent for Cipla.06-Jan-2023

It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved when a business collapses. We note that Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) does have debt on its balance sheet.

Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. Ultimately, if the company can't fulfill its legal obligations to repay debt, shareholders could walk away with nothing. However, a more common (but still painful) scenario is that it has to raise new equity capital at a low price, thus permanently diluting shareholders. Of course, plenty of companies use debt to fund growth, without any negative consequences. The first thing to do when considering how much debt a business uses is to look at its cash and debt together.

The image below, which you can click on for greater detail, shows that at September 2022 Sun Pharmaceutical Industries had debt of ₹38.1b, up from ₹17.8b in one year. But it also has ₹138.4b in cash to offset that, meaning it has ₹100.3b net cash.

A Look At Sun Pharmaceutical Industries' Liabilities

The latest balance sheet data shows that Sun Pharmaceutical Industries had liabilities of ₹167.0b due within a year, and liabilities of ₹13.9b falling due after that. Offsetting this, it had ₹138.4b in cash and ₹123.9b in receivables that were due within 12 months. So it actually has ₹81.3b more liquid assets than total liabilities.

This surplus suggests that Sun Pharmaceutical Industries has a conservative balance sheet, and could probably eliminate its debt without much difficulty. Simply put, the fact that Sun Pharmaceutical Industries has more cash than debt is arguably a good indication that it can manage its debt safely.

Fortunately, Sun Pharmaceutical Industries grew its EBIT by 9.1% in the last year, making that debt load look even more manageable. There's no doubt that we learn most about debt from the balance sheet. But it is future earnings, more than anything, that will determine Sun Pharmaceutical Industries's ability to maintain a healthy balance sheet going forward. So if you're focused on the future you can check out this free report showing analyst profit forecasts.

Finally, a business needs free cash flow to pay off debt; accounting profits just don't cut it. While Sun Pharmaceutical Industries has net cash on its balance sheet, it's still worth taking a look at its ability to convert earnings before interest and tax (EBIT) to free cash flow, to help us understand how quickly it is building (or eroding) that cash balance. During the last three years, Sun Pharmaceutical Industries produced sturdy free cash flow equating to 58% of its EBIT, about what we'd expect. This free cash flow puts the company in a good position to pay down debt, when appropriate.

Drug major Sun Pharmaceutical Industries on Tuesday said its consolidated net profit for Q3 FY23 rose 5% to ₹2,166 crore as compared to ₹2,058.8 crore year-on-year (YoY).31-Jan-2023

There are other category defining brands such as Coldact & Flustat (cold & flu), Brustan, Painamol & Paduden (analgesics), Aspenter, Aspacardin, Nudrate & Fortifikat (lifestyle OTCs), Gestid (digestives) and Chericof (cough).

So company's is a debt free company. We should think about the company to invest our hard earned money.

All details listed in the content above.